Reply to van Deun and Decroo-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Reply to van Deun and Decroo

Published:2020-12-20 Issue:12 Volume:72 Page:e1168-e1169
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Cegielski J Peter¹,Udwadia Zarir F²,Viiklepp Piret³,Yim Jae-Joon⁴,Menzies Dick⁵

Affiliation:

1. Division of Tuberculosis Elimination, U.S. Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA

2. PD Hinduja National Hospital and Medical Research Institute, Mumbai, India

3. Estonian Tuberculosis Registry, National Institute for Health Development, Tallinn, Estonia

4. Division of Pulmonary and Critical Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea

5. Montreal Chest Institute & McGill International TB Centre, Montreal, Quebec, Canada

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciaa1875/36246107/ciaa1875.pdf

Reference10 articles.

1. How second-line injectable drugs work;Van Deun;Clin Infect Dis,2021

2. Aminoglycosides and capreomycin in the treatment of multidrug-resistant tuberculosis: individual patient data meta-analysis of 12 030 patients from 25 countries, 2009–2016;Cegielski;Clin Infect Dis,2020

3. Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline;Nahid;Am J Respir Crit Care Med,2019

4. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis;Ahmad;Lancet,2018

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Correction to: Reply to van Deun and Decroo;Clinical Infectious Diseases;2022-04-23

2. Acquired rifampicin resistance during first TB treatment: magnitude, relative importance, risk factors and keys to control in low-income settings;JAC-Antimicrobial Resistance;2022-03-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3